| Aug 7 |
Q2 2024 BioXcel Therapeutics Inc Earnings Call
|
| Aug 6 |
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 6 |
BioXcel Therapeutics GAAP EPS of -$0.21 beats by $0.57, revenue of $1.1M in-line
|
| Aug 6 |
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
|
| Aug 5 |
BioXcel Therapeutics Q2 2024 Earnings Preview
|
| Jul 30 |
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
|
| Jul 16 |
BioXcel Therapeutics expects 141% Y/Y revenue surge for Q2
|
| Jul 16 |
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
|
| Jun 25 |
BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
|
| Jun 25 |
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
|
